TScan Therapeutics (TCRX) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for TScan Therapeutics (TCRX) over the last 5 years, with Q3 2025 value amounting to -$0.28.
- TScan Therapeutics' EPS (Weighted Average and Diluted) fell 1200.0% to -$0.28 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.12, marking a year-over-year decrease of 1666.67%. This contributed to the annual value of -$1.13 for FY2024, which is 1700.38% up from last year.
- TScan Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.28 in Q3 2025, which was down 1200.0% from -$0.28 recorded in Q2 2025.
- Over the past 5 years, TScan Therapeutics' EPS (Weighted Average and Diluted) peaked at $0.38 during Q4 2021, and registered a low of -$7.69 during Q2 2021.
- For the 5-year period, TScan Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.81, with its median value being -$0.32 (2024).
- Data for TScan Therapeutics' EPS (Weighted Average and Diluted) shows a peak YoY increase of 9180.75% (in 2022) and a maximum YoY decrease of 30263.16% (in 2022) over the last 5 years.
- TScan Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at $0.38 in 2021, then plummeted by 302.63% to -$0.77 in 2022, then skyrocketed by 85.71% to -$0.11 in 2023, then crashed by 181.83% to -$0.31 in 2024, then grew by 9.68% to -$0.28 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.28 in Q3 2025, compared to -$0.28 in Q2 2025 and -$0.26 in Q1 2025.